Nanolynx Biologics AG
Conditionally active nanobody-drug conjugates (Smart NDCs)
Nanolynx Biologics is a platform-enabled therapeutics company developing conditionally active nanobody-drug conjugates (CA-NDCs) for solid tumors. Powered by one of the world's largest nanobody datasets, our IntelliBody™ platform combines tumor-selective activation with superior tissue penetration to widen the therapeutic window of targeted cancer therapies.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
12.06.2026
MassChallenge Switzerland selects its 2026 accelerator cohort (startupticker.ch)
No milestones
No Jobs
No videos and documents
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
Nanolynx Biologics AG
Conditionally active nanobody-drug conjugates (Smart NDCs)
Website:
www.linkedin.com/company/nanolynx-biologics/
Headquarter:
Allschwil
Foundation Date:
December 2025
Technology:
- Biotech
Sectors:
- Biotech
- Cancer
- Drug development platforms
- Drug discovery
- Machine Learning / AI
- Research and development
- Protein drugs
Support received
